Figure 2
Downregulation of miR-26a in aortic intima of HFD-treated ApoE−/− mice and ox-LDL-treated HAECs.
(a) Preparation of aortic intima samples for PCR analysis. (b and c) Real-time RT-PCR analysis of the endothelial cell marker CD31 and the smooth muscle cell marker smMHC in the aortic intima, media and adventitia. n = 4 mice. (d) Real-time RT-PCR analysis of miR-26a in aortic intima, media and adventitia. n = 18 mice. (e) miR-26a expression in aortic intima. n = 4 mice in each group. (f) miR-26a levels in predilection (P) and nonpredilection (NP) sites of the aortic intima. n = 5 mice in each group. (g) miR-26a expression in HAECs treated with ox-LDL at different concentrations. n = 4 batches of cells. (h) miR-26a expression in HAECs treated with ox-LDL (25 μg/ml) for 0, 24, or 48 hours. n = 5 batches of cells. (i) miR-26a levels in the presence of LOX1 antagonist κ-carrageenan (125 μg/ml, 24 h). n = 5 batches of cells. The data are presented as the mean ± S.E.M., *p < 0.05.
